natgillin/translations-raw huggingface dataset:
A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 and 2 for use in the treatment of irritable bowel syndrome, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain or inflammatory bowel disease. 
Spoj za uporabu sukladno patentnom zahtjevu 10, naznačeno time, da je terapija namijenjena bolesti izabranoj iz skupine sastavljene od sindroma iritabilnog crijeva, boli povezane sa sindromom iritabilnog crijeva, funkcionalne konstipacije, funkcionalnog proljeva, kronične idiopatske konstipacije, sindrom funkcionalne boli abdomena, funkcionalne anorektalne boli i upalne crijevne bolesti.
In one embodiment, the trimming means of the first pair are arranged in a plane which is parallel with the vehicle's y-z plane, and a distance away from the centre of gravity; and the trimming means of the second pair are arranged in the x-y plane and along the x axis. 
Podvodno vozilo prema zahtjevu 1, pri čemu je prvi par elemenata za uravnoteženje (10a, b) smješten u ravnini paralelnoj s ravninom y-z vozila i udaljen je od težišta vozila (CG); dok je drugi par elemenata za uravnoteženje (124, b) smješten u ravnini x-y i uzduž x osi.
The formulation in the form of hard or soft gelatine capsule, tablet, coated tablet according to claim 18 wherein said composition consists of 2 to 17 parts by weight of beeswax, 5 to 30 parts by weight of honey, and 65 to 90 parts by weight of cocoa butter on a total of 100 parts by weight. 
Formulacija u obliku tvrde ili meke želatinske kapsule, tableta, obložene tablete u skladu s patentnim zahtjevom 18, naznačena time, da se navedeni pripravak sastoji od 2 do 17 težinskih udjela pčelinjeg voska, 5 do 30 težinskih udjela meda 1 65 do 90 težinskih udjela kakao maslaca od ukupno 100 težinskih udjela .
The particle of claim 8, wherein the polymerase is an alphavirus replicase. 
Čestica u skladu s patentnim zahtjevom 5, naznačena time što je polimeraza alfavirusna replikaza.
Bradykinin and kallidin are released from their protein precursors (known as kininogens), by proteolytic enzymes named kininogenases. 
Bradikinin i kalidin se oslobađaju iz njihovih proteinskih prekursora (poznati kao kininogeni), pomoću proteolitičkih enzima nazvanih kinogenaze.
The bottles containing the light stabilising composition in the indicated amounts as well as a bottle with a control sample were exposed to simulated sunlight by a Xenon lamp (Atlas Material Testing Technology). 
Boce koje sadržavaju pripravak za stabiliziranje na svjetlo u navedenim količinama, kao i boce s kontrolnim uzorkom, se izlože simuliranom sunčevom svjetlu pomoću Xenon lampe (Atlas Material Testing Technology).
A composition as recited in claim 41, wherein said composition consists essentially of a single stereoisomer. 
Tvar kako je nabrojena u jednom ili više od prethodnih patentnih zahtjeva, pri čemu se navedena tvar sastoji u osnovi od pojedinačnog stereoizomera.
The performed experiments showed that the fertility and the structure of the soil and the yield of the crop were improved in a remarkable manner by the use of the OMB fertilizer. The obtained results exceed, even for 70 %, the results achieved by the use of prior art artificial mineral fertilizers, which in the long term - as explained in the introductory part of this specification - also deteriorate the structure and the fertility of the soil as they impede the renewal of humus. 
95 g + HA = heteroauksini, BG = bios skupina Provedeni pokusi pokazuju da su se plodnost i struktura tla, kao također i prinos, bitno poboljšali s upotrebom dobivenog gnojiva, čak do 70% u usporedbi s upotrebom klasičnih mineralnih gnojiva, čija upotreba, kako je već rečeno, kvari strukturu i plodnost tla, jer se ne obnavlja humus.
The compound according to Claim 1, which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, enantiomer R, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-ona, ili njegova farmaceutski prihvatljiva sol.
-SOR1a, -SO2R1a, and -SO2NR1aR1b, wherein R1a, and R1b are independently selected from the group consisting of 
(20)-SO+NRa,Rz, gdje Ra,1 Ray su neovisno odabrani iz skupine koja sadrži (a) vodik,
Said talc silicified preferably comprising talc purified and colloidal silicon dioxide preferably in the amount of 0.667 mg of talc purified and 1.333 mg of colloidal silicon dioxide for 2 mg of talc silicified. 
Navedeni silificirani talk poželjno sadrži pročišćeni talk i koloidni silicijev dioksid poželjno u količini od 0,667 mg pročišćenog talka 1 1,333 mg koloidnog silicijeva dioksida za 2 mg silificiranog talka.
The method of claim 37, wherein said third polymeric material is said polycarboxylic acid polymer that is at least partially neutralized, said method comprising dispersing a polycarboxylic acid polymer in a solvent, optionally with a buffer agent, and adding base to at least partially neutralize the polycarboxylic acid polymer to form the inner coating preparation. 
Postupak za koji se traži zaštita patentom u patentom zahtjevu 11 ili patentnom zahtjevu 12, spomenuti postupak sadrži disperziju polimera polikarboksilne kiseline u otapalu, izborno s puferskim sredstvom, i dodavanje baze da se barem delimično neutralizira polimer polikarboksilne kiseline da bi se formirao preparat unutarnje obloge.
In a particular aspect, a method of the present invention is characterized in that the redox cofactor is regenerated if the cofactors NAD(P)H/NAD(P)+ are used, in particular for the reduction of D-glucosone, consuming a cosubstrate in particular selected from an alcohol, lactic acid and salts thereof, pyruvic acid and salts thereof, oxygen, hydrogen and/or formic acid and salts thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time, da se redoks kofaktor regenerira ako se koriste kofaktori NAD(P)H/NAD(P)*, osobito za redukciju D-glukozona u D -fruktozu, konzumiranjem nosača osobito odabranih između alkohola, mliječne kiseline i njenih soli, piruvinske kiseline i njihovih soli, kisika, vodika 1 / ili mravlje kiseline 1 njihovih soli.
Where the selected paramyxovirus is RSV it is preferred that iota-carrageenan or fucoidan be applied as a predominant or sole sulfated polysaccharide ingredient for prophylactic or therapeutic administration, because iota-carrageenan and fucoidan yielded the best results in the experimental set-ups. The pathological conditions or diseases referred to herein in connection with prophylactic or therapeutic administration of carrageenan comprise acute bronchitis, chronic bronchitis, rhinitis, sinusitis, croup, acute bronchiolitis, pharyngitis, tonsillitis, laryngitis, tracheitis, asthma and pneumonia. 
Jota-karagenan namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se navedeno patološko stanje ili bolest bira iz skupine koju čine akutni bronhitis, kronični bronhitis, rinitis, sinusitis, krup, akutni bronhiolitis, faringitis, tonzillitis, laringitis, traheitis, astma i pneumonija, te što se navedeni simptom bira iz skupine koju čine groznica, bol, vrtoglavica, tresavica, znojenje, te dehidracija.
Method of biological treatment and post-treatment of wastewater according to claim 7 wherein the biologically treated water from biological reactor (1) flows into the sedimentation zone (33) at balanced flow rate, which is lower than the flow rate of pumping wastewater and sludge from back-flushing of the filtration device (2) by the pumping device (17, 63). 
Postupak biološke obrade i naknadnog prečišćavanja otpadne vode prema patentnom zahtevu 7, naznačeno time da, biološki obrađena voda iz biološkog reaktora (1) teče u sedimentacionu zonu (33) ravnomernom brzinom protoka, koja je niža od brzine protoka pumpanja otpadne vode i mulja iz povratnog ispiranja filtracionog uređaja (2) putem uređaja za pumpanje (17, 63).
A mixture of PEG-40 stearate and polysorbate 80 as emulsifyer, A mixture of methylcellulose and xanthan gum as foam stabilizer, A mixture of dimethyl isosorbide and propylene glycol as moisturizer, to pH 4.5 with Sodium hydroxide as neutralizer, ad 100 purified water as external phase, and a propellant as foaming aid for the manufacture of a medicament packed in a container with an outlet valve for the treatment of rosacea or acne. 
d) mješavinu PEG-40 stearata i polisorbata 80 kao emulgator, 6) mješavinu metilceluloze i ksantan gume kao stabilizator pjene, f$) mješavinu dimetil izosorbida i propilen glikola kao ovlaživača, do pH 4.5 sa natrijevog hidroksida kao neutralizatora, do 100 pročišćenu vodu kao eksternu faze, 15
A compound selected from the group consisting of or a stereoisomer, tautomer, solvate, or oxide, or pharmaceutically acceptable salt thereof. 
Spoj, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih:
The method of claim 10, wherein the compound is represented by formula (Ia): 
Spoj u skladu sa patentnim zahtjevom 1 predstavljen formulom (Ia): gdje
A kit of the invention preferably includes packaging and printed instructions for its use, e.g., on the packaging or package insert. 
Preferira se da komplet u skladu s izumom uključuje pakiranje i štampane upute za njegovo korištenje, npr., na pakiranju ili unutar njega.
Then, a ceramic or glass component or insert, for example, the fitment plug 36, 136, 236, 436, 636 or the retainer(s) 34, 134, 234, 334, 534 may be positioned on top of the melting material. 
136, 236, 436, 636), koji se u najmanju ruku dijelom nalazi u unutarnjem prolazu grla spremnika i ima prolaz (66, 266, 466, 666) i radijalnu vanjsku površinu (62.
said Taxol molecules are each conjugated through the N-terminal amine group and through the amine groups on the lysines at positions 10 and 15 of the Angiopep-2 sequence. 
(c) svaka od navedenih molekula Taxola je konjugirana kroz N-terminalni kraj aminske skupine i kroz aminske skupine na lizinima na položajima 10 1 15 u Angiopep-2 sekvenci.
communicatively coupling a second airline remote station (5) to a third interface (35c) of the ground station (35); 
- <- Komunikacijsko uparivanje druge daljinske zrakoplovne postaje (5) s trećim sučeljem (35c) zemaljske postaje
A process according to claim 14, wherein said homologues have an amino acid identity of at least 98%, preferably of at least 99%, and contain valine as amino acid in the position 239 of the amino acid sequence according to SEQ ID No. 
Postupak prema zahtjevu 14, naznačen time da navedeni homolozi imaju identičnost amino kiseline od barem 98%, poželjno od barem 99%, te sadrže valin kao amino kiselinu na položaju 239 sekvence amino kiseline u skladu sa SEQ ID No.
The method of claim 11, wherein the at least two pump segments (103) are configured to be angularly positioned relative to the roller head (203) when the at least two pump segments engage the roller head. 
Postupak prema zahtjevu 11, naznačen time, da su najmanje dva segmenta (103) sisaljke oblikovani za kutni položaj u odnosu na glavu valjka (203) kada najmanje dva segmenta sisaljke zahvaćaju na glavu valjka.
The method according to claim 8, wherein at least one X-ray amorphous phase or a glassy phase is present as a secondary phase in the range of 1 to 10% by weight. 
Postupak sukladno barem jednom od zahtjeva 1 do 5, naznačen time što industrijski nusproizvodi i procesna praškasta sredstva se koriste kao sredstva za ispravljanje za sirove smjese obroka.
(wherein RD1, RD2, RD3, RD4, Y, substituent group C and substituent group D are same as those of item 1). (Item 17) 
-C(S0)-NRYR"9, (gdje R"', R*, R'*, R'", Y, supstituentska skupina C, i supstituentska skupina D imaju isto značenje kao što su navedeni u zahtjevu 1).
Preferably, step (c) is carried out at pH 6.0±0.2, for example in the presence of 1 mM MES (N-morpholinoethanesulfonic acid). 
Poželjno, korak (c) se provodi kod pH 6.0 # 0.2 na primjer u prisutnosti 1mM MES-a (N-morfolinoetansulfonska kiselina).
CCI-779 for use according to Claim 1, wherein the papillary renal cell carcinoma is selected from hereditary type I papillary renal cell carcinoma, hereditary type II papillary renal cell carcinoma and sporadic papillary renal cell carcinoma. 
CCI-779, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se uznapredovali papilarni karcinom bubrežnih stanica bira između nasljednog papilarnog karcinoma bubrežnih stanica tip 1, nasljednog papilarnog karcinoma bubrežnih stanica tip II i sporadičnog papilarnog karcinoma bubrežnih stanica.
wherein R1, R2 and R3 have the meanings as described under formula I, in the presence of an inert organic solvent to a mixture comprising an organic nitrite of formula III R4—O—N═O (III), 
NH, Rz R, pri čemu Ri, R2 i R3 imaju značenja kao što je opisano pod formulom 1, u prisutnosti inertnog organskog otapala u smjesu koja sadrži organski nitrit s formulom III
Methods and Uses 
Postupci i uporabe
Liquefied gas treatment system for vessel 
POSTUPAK OBRADE UKAPLJENOG PLINA NA BRODU
Another aspect of the present invention pertains to uses of the compounds of Formula (I), as described herein, for the manufacture of a medicament for use in raising HDL in an individual. 
Slijedeći aspekt prikazanog izuma odnosi se na uporabu spojeva Formule (T), kako je već ovdje opisana, za izradu lijeka za uporabu u podizanju HDL kod pojedinca.
Number of best diagonals: 5 
(21) Broj predmeta:
As an adhesive, thereby, the product Prefere 6000 of the company Dynea was used. 
Kao adheziv je pri tome bio korišten proizvod Prefere 6000 kompanije Dynea.
has reduced effector function; or 
(i) nema efektornu funkciju; ili
Enhancement of transport of therapeutic molecules across the blood brain barrier 
POBOLJÅ AVANJE TRANSPORTA TERAPIJSKIH MOLEKULA KROZ KRVNO-MOŽDANU BARIJERU
The off-white solid was dried under vacuum at 30°C. 
Mutno bijela krutina se osuši pod vakuumom pri 30 "€.
(A1f) a phenyl-substituted lower alkoxy group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group), or a pyperazyl group represented by the general formula (A2): 
(Alf) fenil-supstituiranu skupinu niži alkoksi s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (supstituentima) na fenilnoj skupini), ili piperazilnu skupinu prikazanu općom formulom (A2):
In the first reaction step, 7-ethylcamptothecin of formula II is oxidized with hydrogen peroxide in acetic acid under formation of 7-ethylcamptothecin 1-oxide of formula III which in the second reaction step is dissolved-in the solvent system dioxane-acetonitrile-water and the solution is irradiated with UV light in the presence of sulfuric acid to afford the desired 7-ethyl-10-hydroxycamptothecin (see US 4 473 692 and US 4 513 138 and Zhongguo Yaowu Huaxue Zazhi 2001, 11 (4), 238-240). 
U prvom koraku 7-etilkamptotecin formule II kojeg se u drugom koraku otapa u sustavu otapala dioksan/acetonitril/voda, a otopinu ozrači UV svjetlom, u prisutnosti sumporne kiseline, kako bi se dobilo željeni 7-etil-10-hidroksikamptotecin (vidjeti dokumente US 4 473 692 i US 4 513 138, te Zhongguo Yaowu Huaxue Zazhi: 11 (4), 238-240, (2001.)).
an inner stator housing (25) that extends between the stator (16) and the heat sink (23), and 
- < unutrašnje kućište statora (25) koje se proteže između statora (16) i uređaja za hlađenje (23), 1
An antibody-drug conjugate (ADC) for use in a method for treating a cancer, reducing tumor growth and/or causing tumor regression in a patient, the ADC comprising an antibody or antigen-binding fragment thereof and a cytotoxin, wherein the antibody or antigen-binding fragment of the first ADC specifically binds EGFRvIII and also binds the junctional peptide of SEQ ID NO:148 and/or the peptide of SEQ ID NO:165, and the method comprising administering to a patient in need thereof the ADC and an additional ADC comprising an antibody or antigen-binding fragment thereof and a cytotoxin, wherein the antibody or antigen-binding fragment of the additional ADC specifically binds EGFRvIII but does not bind the junctional peptide of SEQ ID NO:148 or the peptide of SEQ ID NO:165, and wherein the antibody or fragment thereof of the additional ADC comprises a combination of HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 amino acid sequences of SEQ ID NOs: 36/38/40/44/46/48. 
Konjugat antitijela 1 lijeka (ADC) za primjenu u metodi za liječenje raka, koji smanjuje rast tumora i/ili izaziva regresiju tumora kod pacijenta, pri čemu ADC obuhvaća antitijelo ili njegov fragment koji se vezuje za antigen i citotoksin, naznačeno time, što se antitijelo ili njegov fragment koji se vezuje za antigen iz ADC-a specifično vezuje za EGFRYVIII i također se vezuje za zglobni peptid sa SEQ ID NO:148 i/ili peptid sa SEQ ID NO:165, a metoda obuhvaća primjenu ADC-a i dodatnog ADC-a koji obuhvaća antitijelo ili njegov fragment koji se vezuje za antigen 1 citotoksina kod pacijenta kojemu je potreban, naznačeno time, što se antitijelo ili fragment koji se vezuje za antigen iz dodatnog ADC-a specifično vezuje za EGFRYVIII, ali se ne vezuje za zglobni peptid sa SEQ ID NO:148 ili peptid sa SEQ ID NO:165, 1 naznačeno time, što antitijelo ili njegov fragment iz dodatnog ADC-a obuhvaća kombinaciju aminokiselinskih sekvenci HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sa SEQ ID NO: 36/38/40/44/46/48.
Biological activity of compounds of formula (I). 
1. = Spoj s formulom (I) R2 >NH R3
The communication apparatus according to claim 1, wherein the amount of resource per layer for receiving the ACK/NACK information on the plurality of layers is determined according to the following equation: 
Terminalni uređaj sukladno zahtjevu 1, naznačen time da je kontrolna informacija signal potvrdne/negativne potvrde, ACK/NACK.
The rotational drive of the motor can be converted into a translational drive by having the spindle interact with a thread of a drive shaft. 
Rotacijski pogon motora može biti pretvoren u translacijski pogon pomoću interakcije vratila s navojem pogonske osovine.
The precursor material of claim 1, wherein the precursor material has a tap density in the range from 0.8-2.8 g/cm3. 
Postupak prema zahtjevu 13, u kome prekursor materijal ima nasipnu gustoću u rasponu od 0,8 do 2,8 g/cm3.
An anti-CD20 antibody formulation comprising 20-300 mg/mL ofatumumab, wherein the formulation further comprises 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2% polysorbate 80 and adjusted to pH 5.0 to 7.0. The anti-CD20 antibody formulation of Claim 1, wherein the formulation is stable at a temperature of 5°C for at least 2 years. 
Formulacija protutijela anu-CID20, naznačena time, da obuhvaća od 20 do 300 mg/mL, ofatumumaba, od 10 do 100 miM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0.2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,8 do 7,0, pri čem se ona upotrebljava u liječenju imunološke bolesti i/ili autoimune bolesti.
Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable bases are chosen from the group comprising ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine. 
Farmaceutski sastav prema zahtjevu 16, naznačen time, da su navedene fiziološki prihvatljive lužine odabrane iz skupine koju čine: amonijev hidroksid, kalcijev hidroksid, magnezijev karbonat, natrij-vodikov karbonat, kalij-vodikov karbonat, arginin, betain, kafein, kolin, N,N-dibenziletilendiamin, dietilamin, 2-dietilaminoetanol, 2-dimetilaminoetanol, etanolamin, etilendiamin, N-etilmorfolin, N-etilpiperidin, N-metilglukamin, glukamin, glukozamin, histidin, N-(2-hidroksietil)piperidin, N-(2-hidroksietil)pirolidin, izopropilamin, lizin, metilglukamin, morfolin, piperazin, piperidin, teobromin, trietilamin, trimetilamin, tripropilamin i trometamin.
Use of an effective amount of a compound of claim 1 or claim 20 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pain, urinary incontinence, an ulcer, irritable-bowel syndrome or inflammatory-bowel disease. 
Farmaceutski pripravak naznačen time da sadrži učinkovitu količinu spoja prema zahtjevu 1 ili zahtjevu 20 ili njegovu farmaceutski prihvatljivu sol za uporabu kod liječenja boli, uriname inkontinencije, čira, sindroma iritabilnog crijeva ili upalnog poremećaja crijeva.
separating the suspension into three phases, i.e. 
odvajanja suspenzije koja sadrži mokro mljevena, nefermentirana zrna kakaa u tri faze, tj.
The process according to claim 11, wherein the dihydrogen is obtained by decomposition of an ammonium formate. 
Postupak za industrijsku sintezu spoja formule (1) u skladu s patentnim zahtjevom 11, naznačen time, da je dihidrogen dobiven razgradnjom amonijevog formijata.
a contiguous sequence of the human λ light chain locus that spans from hVλ5-52 through hVλ1-40 and a contiguous sequence of the human λ light chain locus that spans from hVλ3-29 through hVλ3-1. An isolated cell that expresses an antibody comprising a light chain that comprises a rearranged human Vλ/Jλ sequence and a mouse Ck sequence, wherein the cell is from, or obtainable from, the mouse of any one of the preceding claims, and wherein the rearranged human Vλ/Jλ sequence is operably linked to a mouse Ck gene at an endogenous mouse immunoglobulin k light chain locus. 
Hibridom koji sadrži preuređenu sekvencu gena imunoglobulinskog lakog lanca dobivenu iz miša prema patentnom zahtjevu 1, preuređenu sekvencu koja sadrži segment gena hV2, segment gena hJA i mišji gen CK na lokusu endogenog mišjeg imunoglobulinskog lakog lanca K, naznačen time, što se na spomenutom lokusu održava element intronskog pojačivača K uzvodno od gena CK (označen kao EKi) 1 pojačivač 3' K nizvodno od gena CK (označen kao EK3'), pri čemu hibridom izražava antitijelo koje sadrži laki lanac koji sadrži preuređenu humanu sekvencu VA-JA i mišju sekvencu CK.
or their pharmaceutically acceptable salts and/or stereoisomeric forms. 
ili njegove farmaceutski prihvatljive soli i/ili stereoizomerni oblici.
ii) having at least 99% identity to SEQ ID NO: 3 and is a hybrid capsid comprising regions of the AAV3B and AAV8 capsids. 
ima identitet najmanje 99 %-tno jednak sekvenci SEQ ID NO: 3 i jeste hibridni kapsid koji sadrži regije kapsida AAV3B i AAV8.
A crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]-piperidine, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 4.44±0.20, 10.22±0.20, 17.16±0.20, and 21.78±0.20. 
Kristalna hidrokloridna sol 4-[2-(2,4,6-trifluorofenoksimetil)fenil]-piperidina, naznačena time, da mu vrijednosti difrakcijskih vrškova na 20 iznose 4.44+0.20, 10.22+0.20, 17.16+0.20 1 21.78+0.20 u uzorku rendgenske difrakcije u prašku.
In addition, the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal. 
Uz to, aktivne spojeve se može ugraditi u brzootapajuće, te u pripravke 1 formulacije za modificirano otpuštanje ili produljeno otpuštanje, gdje takve formulacije za prođuljeno-otpuštanje su po mogućnosti dvomodne.